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Abstract
Background—The utility of estimated glomerular filtration rate (eGFR) and albuminuria for 
cardiovascular prediction is controversial.
Methods—We meta-analyzed individual-level data from 24 cohorts (with a median follow-up 
time longer than 4 years, varying from 4.2 to 19.0 years) in the Chronic Kidney Disease Prognosis 
Consortium (637,315 participants without a history of cardiovascular disease) and assessed C-
statistic difference and reclassification improvement for cardiovascular mortality and fatal and 
non-fatal cases of coronary heart disease, stroke, and heart failure in 5-year timeframe, contrasting 
prediction models consisting of traditional risk factors with and without creatinine-based eGFR 
and/or albuminuria (either albumin-to-creatinine ratio [ACR] or semi-quantitative dipstick 
proteinuria).
Findings—The addition of eGFR and ACR significantly improved the discrimination of 
cardiovascular outcomes beyond traditional risk factors in general populations, but the 
improvement was greater with ACR than with eGFR and more evident for cardiovascular 
mortality (c-statistic difference 0.0139 [95%CI 0.0105–0.0174] and 0.0065 [0.0042–0.0088], 
respectively) and heart failure (0.0196 [0.0108–0.0284] and 0.0109 [0.0059–0.0159]) than for 
coronary disease (0.0048 [0.0029–0.0067] and 0.0036 [0.0019–0.0054]) and stroke (0.0105 
[0.0058–0.0151] and 0.0036 [0.0004–0.0069]). Dipstick proteinuria demonstrated smaller 
improvement than ACR. The discrimination improvement with kidney measures was especially 
evident in individuals with diabetes or hypertension but remained significant with ACR for 
cardiovascular mortality and heart failure in those without either of these conditions. In 
participants with chronic kidney disease (CKD), the combination of eGFR and ACR for risk 
discrimination outperformed most single traditional predictors; the c-statistic for cardiovascular 
mortality declined by 0.023 [0.016–0.030] vs. <0.007 when omitting eGFR and ACR vs. any 
single modifiable traditional predictors, respectively.
Interpretation—Creatinine-based eGFR and albuminuria should be taken into account for 
cardiovascular prediction, especially when they are already assessed for clinical purpose and/or 
cardiovascular mortality and heart failure are the outcomes of interest (e.g., the European 
guidelines on cardiovascular prevention). ACR may have particularly broad implications for 
cardiovascular prediction. In CKD populations, the simultaneous assessment of eGFR and ACR 
will facilitate improved cardiovascular risk classification, supporting current CKD guidelines.
Funding—US National Kidney Foundation and NIDDK
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Individuals with chronic kidney disease (CKD) are at high risk of cardiovascular disease,1 
and approximately half die of cardiovascular disease without reaching end-stage renal 
disease.2 Two key kidney measures defining and staging CKD, glomerular filtration rate 
(GFR) and albuminuria, are consistently associated with high cardiovascular risk in a broad 
range of populations.3 However, previous studies examining whether these kidney disease 
measures improve cardiovascular risk prediction beyond traditional risk factors have 
demonstrated conflicting results,4–9 leading to controversy in primary prevention guidelines 
as to whether CKD status should be taken into account for cardiovascular risk 
classification.10,11
Significant associations do not necessarily result in risk prediction improvement,12 and prior 
studies varied substantially in terms of study population, cardiovascular outcomes or kidney 
disease measures of interest (often omitting albuminuria), and statistics for assessing 
prediction improvement,4–9 making it difficult to resolve the discrepancy between risk 
relationship vs. prediction in this context, and to achieve definitive conclusions. Therefore, 
we used the extensive database of the CKD Prognosis Consortium (CKD-PC) to examine 
the role of both measures of CKD in improving the prediction of various cardiovascular 
outcomes beyond traditional risk factors, using standard definitions and analytic approaches 
across contributing cohorts. We addressed these issues in primary prevention (i.e., persons 
without history of cardiovascular disease), where traditional risk factors are most relevant 
for cardiovascular risk prediction.5
Methods
Study Design
Details of the CKD-PC were previously described3,13 or can be found in the website: 
www.jhsph.edu/ckdpc. This analysis used data from 24 cohorts (19 general population 
cohorts, three high-risk cohorts of subjects with diabetes mellitus, and two CKD cohorts 
exclusively enrolling CKD patients), all with data on fatal and non-fatal cardiovascular 
outcomes and a median follow-up time longer than 4 years. This study was approved by the 
Institutional Review Board at the Johns Hopkins Bloomberg School of Public Health.
Study Variables at Baseline
Estimated GFR (eGFR) was calculated by the CKD-EPI creatinine-based equation.13,14 We 
focused on creatinine-based eGFR, since this is widely used in clinical practice.14 We 
preferred urine albumin-to-creatinine ratio (ACR) (timed urine albumin excretion was 
considered equivalent) as the measure of albuminuria15 but also accepted urine protein-to-
creatinine ratio (PCR) and semi-quantitative assessment of proteinuria using a dipstick test.
We defined the traditional risk factors to be race/ethnicity (white, black, Asian, Hispanic, 
and other) and those in the Framingham prediction model for general cardiovascular risk:16 
age, sex, systolic blood pressure, antihypertensive drug use, total and high-density 
lipoprotein cholesterols, smoking status (current/not), and diabetes (defined as fasting 
glucose ≥7.0 mmol/L, non-fasting glucose ≥11.1 mmol/L, hemoglobin A1c ≥6.5%, use of 
glucose lowering drugs, or self-reported diabetes). Hypertension was defined as systolic 
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blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of 
antihypertensive medication.
Cardiovascular Outcomes
Outcomes studied were cardiovascular mortality (death from myocardial infarction, stroke, 
heart failure, or sudden cardiac death), coronary heart disease (CHD) (myocardial infarction, 
fatal coronary heart disease, or coronary revascularization), stroke (ischemic and 
hemorrhagic stroke except subarachnoid hemorrhage), and heart failure (hospitalization or 
death due to heart failure) (appendix pp 6–12).
Statistical Analysis
Analyses were restricted to subjects aged 18 years or older without a history of CHD, stroke, 
or heart failure at baseline. Statistics were first obtained within each cohort and then pooled 
by a fixed-effect model, weighting by the number of events in each cohort.17 We first 
investigated the associations of eGFR and albuminuria with cardiovascular outcomes after 
adjusting for each other and traditional risk factors using Cox proportional hazards models 
in the general population and high-risk cohorts combined. We modeled eGFR and ACR 
using linear splines with knots at 30, 45, 60, 75, 90, and 105 ml/min/1.73m2 and 10, 30, and 
300 mg/g, respectively. The reference points were eGFR 95 ml/min/1.73m2 and ACR 5 
mg/g.3 ACR was log-transformed,3 as were all continuous traditional risk factors.11,16
We subsequently estimated the difference in Harrell’s c-statistics between prediction models 
that included or excluded kidney disease measures. To reduce the methodological advantage 
of having several spline terms, compared to the traditional risk factors which were, by 
convention, modeled linearly, in these models, eGFR was modeled with two linear terms (a 
single knot at 60 ml/min/1.73m2), based on the shape of its associations with cardiovascular 
outcomes. Log-ACR and log-PCR were linearly modeled, and dipstick proteinuria was 
categorized as negative (reference), trace, 1+, and ≥2+. In the general population and high-
risk cohorts, we evaluated primarily whether the addition of kidney disease measures 
improves cardiovascular prediction beyond traditional risk factors.
We also meta-analyzed the subpopulation with CKD: participants in the CKD cohorts plus 
those from the other cohorts with low eGFR <60 ml/min/1.73m2 or high albuminuria 
[defined as ACR ≥30 mg/g, PCR ≥50 mg/g, or dipstick proteinuria ≥1+]13). As this setting 
inherently assumes existing data on kidney disease measures for identifying CKD,15 we 
assessed the omission of each of these kidney disease measures and modifiable traditional 
risk factors from the full models with all the predictors. This approach allows a fair 
comparison among every predictor independently of the order of predictors included in the 
models and thus gives unbiased evidence as to which predictors should be used in 
prediction.17
We also evaluated the categorical net reclassification improvement (NRI).18 Given the lack 
of internationally accepted risk thresholds for cardiovascular outcomes, conventional CHD 
risk categories that have been widely used in the literature (<10% [low], 10–19% 
[intermediate], and ≥20% [high] in 10 years - roughly equivalent to <5%, 5%-9%, and ≥10% 
in 5 years)17,19 were applied to each cardiovascular outcome, based on the relatively close 
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annual incidence of new coronary attack, stroke, heart failure, and cardiovascular mortality 
in the US (600,000–800,000 cases for each).20 To provide a practical context for 
reclassification, we also estimated the number needed to screen (NNS).17 This is the 
required number of people to screen for preventing one event under the assumption that 20% 
of high risk individuals who developed cardiovascular events would have been prevented by 
an intervention (for example statins for CHD). To estimate NNS for the US, we assumed the 
population distribution data from NHANES III and risk estimates from all eligible US 
cohorts for each outcome (appendix pp 13–15).17
All models demonstrated good calibration according to visual inspection of observed vs. 
predicted risk and a modified Hosmer-Lemeshow statistic.16 Heterogeneity was quantified 
using the χ2 test and the I2 statistic. We conducted meta-regression analysis to explore 
sources of heterogeneity when we observed high heterogeneity (I2 statistic >75%21). 
Subgroup analyses were performed according to age, sex and race and by hypertension and 
diabetes status. Analyses were conducted using Stata/MP 13 (www.stata.com). A-priori a P-
value below 0.05 was considered significant.
Role of the funding source
The sponsors had no role in the study design, data collection, analysis, data interpretation, or 
writing of the report. KM and JCo had full access to all analyses and all authors had final 
responsibility for the decision to submit for publication, informed by discussions with 
collaborators.
Results
Overall, 637,315 individuals free of CVD history with a mean age of 47 (SD 16) years were 
followed up for a mean of 8.9 years (6 million person-years) (Table 1) after excluding 
146,769 subjects with missing values for eGFR, albuminuria, or traditional risk factors at 
baseline was excluded (appendix pp 13–15).. Almost all blacks were from four US general 
population cohorts, and data for Asians were predominantly from cohorts with dipstick 
proteinuria. The prevalence of low eGFR and high albuminuria were 3.8% (n=23,076) and 
2.9% (n=17,701) (0.6% [n=3,753] with both) in general population cohorts, 22.5% 
(n=7,909) and 13.4% (n=4,699) (4.3% [n=1,506]) in high-risk cohorts, and 56.5% (n=1,075) 
and 75.4% (N=1,434) (46.1% [n=877]) in CKD cohorts, respectively. During follow-up, 
10,605 cardiovascular deaths were reported from 22 cohorts, 6,283 CHD events from 12 
cohorts, 4,180 stroke events from 12 cohorts, and 2,066 HF events from 8 cohorts.
Adjusted cardiovascular risk was relatively constant at eGFR 75–105 ml/min/1.73m2 and 
increased steadily below this range (Figure 1A-1D). The risk gradient was steeper for 
cardiovascular mortality and heart failure compared to CHD and stroke. A J-shaped 
association with elevated risk at eGFR >105 ml/min/1.73m2 was observed for all outcomes 
but was most evident for cardiovascular mortality. Results for eGFR were largely similar 
between studies with data on ACR and dipstick proteinuria (appendix p 23). The 
relationships of ACR to cardiovascular outcomes were largely monotonic on the log-log 
scale (Figure 1E-1H). Similarly to eGFR, the risk gradient was sharper for cardiovascular 
mortality and heart failure compared to CHD and stroke. This pattern was consistent when 
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we meta-analyzed only those studies with all four cardiovascular outcomes (data not 
shown).
C-statistics for cardiovascular outcomes based on traditional risk factors ranged from 0.729–
0.838 in the general and high-risk cohorts and were significantly improved with the addition 
of either or both measures of kidney disease (Figure 2). In line with the risk gradients in 
Figure 1, both kidney disease measures improved discrimination more evidently for 
cardiovascular mortality and heart failure than for CHD and stroke. There were some 
incremental improvements when eGFR and albuminuria were modeled simultaneously. 
Nevertheless, the discrimination improvement was greater with ACR than with eGFR or 
dipstick proteinuria for all cardiovascular outcomes. The results were qualitatively 
consistent across cohorts (appendix pp 24–25). When these kidney disease measures were 
contrasted with the modifiable traditional risk factors by omitting each from the full models, 
ACR contributed to better discrimination more than most of the traditional risk factors for 
all outcomes except CHD (appendix p 26). eGFR was at least as good as most of the 
traditional risk factors. Results were much the same in cohorts with dipstick proteinuria 
(appendix p 27) and for NRI (appendix pp 28–29).
Improvements in discrimination with eGFR and ACR were more evident among individuals 
with diabetes or hypertension compared to those without either of these conditions (Figure 
3). Nevertheless, ACR significantly improved the discrimination for cardiovascular 
mortality and heart failure among those without diabetes or without hypertension (Figure 3). 
The contribution of ACR and eGFR to better discrimination was generally consistent in 
subgroups defined by age, sex, and race (appendix p 30). One exception was considerably 
greater discrimination improvement, particularly for cardiovascular mortality and heart 
failure, with ACR in blacks than in whites (appendix p 30). Again, we observed consistent 
results for NRI (appendix pp 31–33).
In line with the relatively small improvement with kidney disease measures for prediction of 
CHD and stroke, the estimated 5-year NNS of the models with eGFR and/or ACR for these 
outcomes for the US population was not significantly different from that for the model with 
only traditional risk factors (Figure 4). The results were consistent when we restricted to 
hard CHD (myocardial infarction or fatal events). Similar results were observed when we 
applied risk categories for the combination of hard CHD and stroke as recently proposed by 
the American Heart Association and American College of Cardiology (10-y risk <5%, 5–
7.4%, and ≥7.5% rescaling to 5-y) (appendix pp 19–20).11 In contrast, the models with 
kidney disease measures, particularly ACR, significantly reduced the NNS for 
cardiovascular mortality and heart failure (Figure 4). These models estimated the 5-year 
NNS to be between 170 and 500 among those who were initially categorized as at 
intermediate risk with traditional risk factors (appendix p 21).17 Similar patterns were 
observed for cardiovascular mortality with risk categorization taken from the European 
guidelines10 (appendix p 22).
In the CKD population, ACR was again one of the strongest contributors for better 
discrimination for all cardiovascular outcomes (Figure 5). eGFR also significantly 
contributed to better discrimination for cardiovascular mortality and CHD in this population. 
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Better discrimination of cardiovascular mortality with eGFR was confirmed in cohorts with 
dipstick proteinuria (appendix p 34). The combination of eGFR and ACR outperformed any 
single modifiable traditional risk factor, as well as the combination of total and high-density 
lipoprotein cholesterols, for all cardiovascular outcomes, except for diabetes in CHD 
prediction. Largely similar results were found across cohorts (appendix pp 35–38) and when 
NRI was tested (appendix p 39).
Discussion
In this meta-analysis, eGFR and albuminuria independently improved the prediction of 
incident cardiovascular events beyond traditional risk factors. The improvement was greater 
with ACR than with eGFR or dipstick proteinuria and was more evident for cardiovascular 
mortality and heart failure than for CHD and stroke. ACR was superior to most of the 
modifiable traditional risk factors for predicting cardiovascular mortality, heart failure, and 
stroke in the general populations. The prediction improvement with kidney disease measures 
was more evident in those with diabetes or hypertension but was also significant with ACR 
for cardiovascular mortality and heart failure even among those without either of these 
conditions. In the CKD population, the combination of eGFR and ACR outperformed almost 
all single modifiable traditional risk factors and the combination of traditional lipid 
parameters for the prediction of all cardiovascular outcomes.
Several studies have investigated cardiovascular prediction improvement with eGFR and/or 
albuminuria in the primary prevention setting, with some reporting improvement4–6 and 
some not.7,8 With our meta-analysis, we may provide some explanation for the differences 
among them. Two studies with positive results focused on cardiovascular mortality,4,5 a 
cardiovascular outcome strongly related to kidney disease measures in our study, whereas a 
negative study dealt exclusively with CHD.8 The other positive study focused on a CKD 
population, a population in which kidney measures demonstrated superiority to traditional 
risk factors for cardiovascular prediction in our study. Most importantly, neither of two 
negative studies investigated ACR.7,8
ACR was one of the strongest predictors of cardiovascular outcomes other than CHD among 
general populations in our study. Our results also support ACR as a preferable measure of 
albuminuria over dipstick proteinuria, although dipstick has a cost advantage, particularly 
for mass screening.15 The pathophysiological mechanisms linking albuminuria to 
cardiovascular risk are not well understood. Albuminuria mainly results from damage to the 
glomerulus and thus is considered a marker of systemic vascular damage or microvascular 
disease in addition to kidney disease,5 which may explain its strong contribution to 
cardiovascular prediction. Indeed, the role of microvascular disease in the development of 
heart failure has recently attracted attention.22 Also, albumin in urine can directly damage 
the kidney,23 and thus whether these pathological changes in the kidney impact 
cardiovascular system would warrant investigations. Nevertheless, our results are in line 
with the observation that the reduction in albuminuria by renin angiotensin system inhibitors 
is associated with cardiovascular risk reduction.24
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Although weaker than ACR, eGFR also contributed to better cardiovascular prediction in 
several circumstances. Again the pathophysiological mechanisms are not clear but the most 
robust prediction improvement with eGFR was for cardiovascular mortality, particularly in 
those with CKD. This may be because patients with lower eGFR manifest more severe 
cardiovascular disease compared to higher eGFR25 and tend to not receive optimal treatment 
for cardiovascular disease.26 Even for predicting the other cardiovascular outcomes, eGFR 
was not necessarily inferior to the modifiable traditional risk factors.
Even though the change in c-statistic of ~0.005 to ~0.03 by incorporating eGFR and/or ACR 
in prediction models may appear small to modest, it is similar or superior to the 
contributions of most of the individual traditional risk factors including blood pressure, 
lipids, and smoking. Furthermore these values are considerably higher than the increments 
in c-statistic gained by high-sensitivity C-reactive protein, a representative non-traditional 
predictor, in a previous meta-analysis.17 Of note, in contrast to many non-traditional 
predictors, GFR and albuminuria are already measured in several clinical scenarios. Indeed, 
their assessment is recommended among persons with diabetes and/or hypertension,27,28 and 
approximately 290 million tests of serum creatinine are carried out every year in the US.29 
Thus, in these scenarios, their use for cardiovascular risk assessment is cost effective. This 
will be particularly the case for individuals identified as having CKD, and our results 
support the initial cardiovascular risk classification with both eGFR and ACR in CKD, as 
recommended in the Kidney Disease Improving Global Outcomes guidelines.15 Also, it is 
important to keep in mind that cardiovascular risk prediction may be beyond guiding drug 
therapy and may motivate lifestyle modification. Thus, any improvement with existing 
information may be valuable.
Whether the measurement of creatinine-based eGFR and albuminuria should be extended to 
the general population is under debate.30 ACR significantly improved the prediction of 
cardiovascular mortality and heart failure even among those without either diabetes or 
hypertension and reduced the overall NNS for these outcomes compared to models with 
traditional risk factors. These results suggest a potential benefit of expanding the groups for 
ACR assessment for the prediction of cardiovascular mortality and heart failure. The 
European prevention guidelines, indeed, use cardiovascular mortality to scale the risk but 
currently prioritize eGFR over ACR for cardiovascular risk classification and may benefit 
from greater emphasis on ACR.10 In terms of potential target population, ACR assessment 
particularly led to better cardiovascular prediction among blacks in our study, which 
confirms a recent report of stronger association of ACR with incident cardiovascular events 
in blacks than in whites.31 Nevertheless, the cost-effectiveness of screening and subsequent 
life-style/drug interventions should still be evaluated.
Our results should be interpreted in the context of certain limitations. The methods used to 
evaluate creatinine, albuminuria, and traditional risk factors varied across cohorts, despite 
our efforts to standardize definitions. However, this is unlikely to cause bias favoring kidney 
measures. Similarly, the ascertainment of cardiovascular outcomes was not necessarily 
consistent. Nevertheless, we observed qualitatively consistent prediction improvement in 
vast majority of cohorts (appendix pp 24–25). Our study was based on single assessments of 
creatinine-based eGFR and albuminuria.15 However, the misclassification due to their short-
Matsushita et al. Page 8













term variability, if any, would result in conservative estimates, and the traditional risk 
factors were assessed similarly. Direct measurement of GFR or other filtration markers, such 
as cystatin C, was not available in a majority of the cohorts and hence not evaluated. We 
anticipate more evident improvement with eGFR based on cystatin C than with creatinine-
based eGFR.32 Also, confounding by low urine creatinine excretion may be an issue for the 
ACR-risk relationship.33 However, the prediction improvement was observed in studies with 
timed overnight urinary albumin excretion (appendix pp 13–15) and dipstick studies (Figure 
2), which are not corrected for urine creatinine. Most of the blacks in our study were from 
US cohorts. Most Asian cohorts evaluated albuminuria using dipstick, and thus we cannot 
differentiate whether the difference between ACR and dipstick cohorts were confounded by 
racial or regional factors. Further investigation is needed for racial/ethnic groups other than 
Asians, whites, and blacks.
In conclusion, creatinine-based eGFR and albuminuria independently improved 
cardiovascular prediction, particularly for mortality and heart failure. ACR outperformed 
eGFR and most of the modifiable traditional risk factors for these two outcomes, as well as 
stroke, supporting its use for cardiovascular risk assessment in a broad range of settings. 
Among clinical populations, in which the assessment of eGFR and albuminuria is already 
recommended (e.g., individuals with CKD, diabetes, and hypertension), these kidney disease 
measures are especially useful for cardiovascular risk prediction.
Panel: Research in context
Evidence before this study
Electronic searches based on PubMed in addition to manual searches of reference lists of 
prior studies identified a few studies specifically assessing the improvement of 
cardiovascular risk prediction by incorporating either or both kidney measures (estimated 
GFR based on serum creatinine and/or cystatin C) and kidney damage (based on 
albuminuria or proteinuria), exclusively or predominantly in individuals without history of 
cardiovascular disease at baseline.4–9 However, these studies obtained conflicting results 
and varied substantially in terms of study population and method, making it difficult to 
achieve definitive conclusions and leading to inconsistent approaches about how to 
incorporate CKD in cardiovascular risk assessment across different clinical guidelines.10,11
Added value of this study
We meta-analyzed individual-level data from 24 cohorts (637,315 participants without a 
history of cardiovascular disease) and assessed risk prediction improvement with either or 
both of creatinine-based eGFR and albuminuria (ACR or dipstick proteinuria) for 
cardiovascular mortality, coronary disease, stroke, and heart failure. Although creatinine-
based eGFR and albuminuria independently improved cardiovascular prediction in general, 
the improvement was particularly evident for cardiovascular mortality and heart failure. 
ACR outperformed eGFR and most of the modifiable traditional risk factors for these two 
outcomes, as well as stroke. The discrimination improvement with ACR was especially 
evident in individuals with diabetes or hypertension but remained significant for 
cardiovascular mortality and heart failure even in those without either of these conditions. 
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When the analysis was restricted to persons with CKD, the combination of eGFR and ACR 
for risk discrimination outperformed most single traditional predictors, suggesting the value 
of their simultaneous assessment for cardiovascular risk classification.
Implications of all the available evidence
Creatinine-based eGFR and albuminuria should be taken into account for cardiovascular 
prediction, especially when they are already assessed for clinical purpose (e.g., individuals 
with CKD, diabetes, and hypertension), and/or cardiovascular mortality and heart failure are 
the outcomes of interest (e.g., the European guidelines on cardiovascular prevention).10 
ACR may have particularly broad implications for cardiovascular prediction. In CKD 
populations, the simultaneous assessment of eGFR and ACR will facilitate improved 
cardiovascular risk classification, supporting current CKD guidelines.
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Adjusted hazard ratios and 95% CIs (shaded areas or whisker plots) of cardiovascular 
mortality (top row), coronary heart disease (second row), stroke (third row), and heart 
failure (bottom row) according to eGFR (left column) and ACR (right column) in the 
combined general population and high-risk cohorts. The reference is eGFR 95 ml/min/
1.73m2 and ACR 5 mg/g (diamond). Dots represent statistical significance (P<0.05). 
*Adjustments were for age, sex, race/ethnicity, smoking, systolic blood pressure, 
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antihypertensive drugs, diabetes, total and high-density lipoprotein cholesterol 
concentrations, and albuminuria (ACR or dipstick) or eGFR, as appropriate.
In the analyses of eGFR, there were 629,776 participants for cardiovascular mortality, 
144,874 for coronary heart disease, 137,658 for stroke, and 105,127 for heart failure. In the 
analyses of ACR, there were 120,148 participants for cardiovascular mortality, 91,185 for 
coronary heart disease, 82,646 for stroke, and 55,855 for heart failure.
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Difference in C-statistic for cardiovascular outcomes by adding kidney measure(s) to 
traditional models in the combined general population and high-risk cohorts. There was only 
one study with dipstick proteinuria and heart failure, and thus meta-analysis was not 
performed.
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Change in c-statistics for cardiovascular outcomes by adding eGFR, ACR, and both to 
traditional risk factors in general population and high risk cohorts, according to the status of 
diabetes and hypertension.
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Number needed to screen (NNS) for preventing one event among individuals at high risk of 
each CVD outcome. High risk was defined as 5-y risk ≥10%, and NNS is based on the 
assumption of 20% risk reduction by interventions. * indicates statistical significance (p 
<0.05) compared to NNS based on the base model with traditional predictors.
In these analyses there were 27,745 participants for cardiovascular mortality, 17,531 for 
coronary heart disease, 16,869 for stroke, and 19,265 for heart failure.
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C-statistic difference for four cardiovascular outcomes by omitting kidney disease measures 
and traditional risk factors from a model with all risk factors in a CKD population
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